Roche’s Kadcyla is the first targeted therapy to show
Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated ...
Read morePhase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated ...
Read more© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.
© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.